JPRN-jRCT1090220039已完成Unknown
Prognostic Potential of Detection of WT1-mRNA in Acute Myeloid Leukemia - Prognostic Potential of Detection of WT1-mRNA in AM
Shuichi Miyawaki;Division of Hematology, Tokyo Metropolitan Ohtsuka Hospital.0 个研究点目标入组 50 人开始时间: 2010年6月10日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- >= 17age old 至 < 70age old（—）
- 性别
- All
入选标准
- •Untreated, de novo AML patients, who are positive for WT1-mRNA at diagnosis and achieve complete remission after initial remission-induction therapy.
排除标准
- •AML patients who do not meet the above condition.
研究者
相似试验
已完成
Unknown
Measurement of WT1-mRNA in Acute Myeloid Leukemia PatientsAcute Myeloid LeukemiaJPRN-jRCT1090220061Shuichi Miyawaki;Division of Hematology, Tokyo Metropolitan Ohtsuka Hospital.100
招募中
不适用
Significance of WT1 mRNA in the clinical course of lower-risk myelodysplastic syndromes.lower-risk myelodysplastic syndromesJPRN-UMIN000017862Jichi Medical University100
已完成
不适用
WT1 expression as an early predictor for molecular relapse in patients with acute promyelocytic leukemia in first remission with negative PML-RARa after anthracycline-based chemotherapy plus all-trans retinoic acidDiseases of the blood and blood -forming organs and certain disorders involving the immune mechanismKCT0002079The Catholic University of Korea, Seoul St. Mary's Hospital117
进行中（未招募）
不适用
Therapeutic efficacy of Wilms tumor gene (WT1) mRNA-electroporated autologous dendritic cell vaccination in patients with myeloid malignancies and multiple myeloma:a phase II trial.Therapeutic vaccination with dendritic cells loaded with wilms' tumor 1 protein in patients with myeloid malignancies and multiple myelomaMedDRA version: 12.0Level: LLTClassification code 10046859Term: VaccinationMedDRA version: 12.0Level: LLTClassification code 10024329Term: LeukemiaMedDRA version: 12.0Level: LLTClassification code 10028228Term: Multiple myelomaEUCTR2009-015720-28-BEAntwerp University Hospital
尚未招募
1 期
Phase I study of Wilms' tumor gene WT1 peptide vaccination combined with gemcitabine for patients with advanced non-small-cell lung canceradvanced or recurrent non-small-cell lung cancerJPRN-UMIN000005226School of Medicine, Keio University10